On Friday, Novavax, Inc (NASDAQ: NVAX) was 1.00% up from the session before settling in for the closing price of $9.02. A 52-week range for NVAX has been $3.53 – $23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 513.29%. When this article was written, the company’s average yearly earnings per share was at 73.63%. With a float of $153.02 million, this company’s outstanding shares have now reached $160.15 million.
Let’s determine the extent of company efficiency that accounts for 1543 employees. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.
Novavax, Inc (NVAX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 4.47%, while institutional ownership is 58.98%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,350. Before that another transaction happened on Sep 18 ’24, when Company’s Officer proposed sale 7,335 for $13.00, making the entire transaction worth $95,331.
Novavax, Inc (NVAX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to 11.55% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.26, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach 0.10 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Looking closely at Novavax, Inc (NASDAQ: NVAX), its last 5-days average volume was 2.87 million, which is a drop from its year-to-date volume of 9.33 million. As of the previous 9 days, the stock’s Stochastic %D was 60.09%. Additionally, its Average True Range was 0.57.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 20.91%, which indicates a significant decrease from 69.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.64% in the past 14 days, which was lower than the 93.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.63, while its 200-day Moving Average is $10.43. However, in the short run, Novavax, Inc’s stock first resistance to watch stands at $9.31. Second resistance stands at $9.50. The third major resistance level sits at $9.72. If the price goes on to break the first support level at $8.90, it is likely to go to the next support level at $8.68. Now, if the price goes above the second support level, the third support stands at $8.49.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are 160,185K outstanding shares of the company, which has a market capitalization of 1.47 billion. As of now, sales total 983,710 K while income totals -545,060 K. Its latest quarter income was 84,510 K while its last quarter net income were -121,300 K.
